This health-economic analysis investigated the cost, cost-effectiveness and cost-utility of intravenous paricalcitol compared with oral calcitriol and oral and intravenous alfacalcidol.

Patients were randomly assigned to receive oral paricalcitol or placebo. Dosing took place three times weekly, starting at 2 µ g or 4 µ g per dose (two trials) or once daily, starting at 1 µ g ...

aCenter for Renal Translational Medicine/Institute for Metabolomic Medicine, University of California San Diego, San Diego, CA, United States bDepartment of Clinical and Molecular Medicine, Faculty of ...

The prevalence of anemia (Hb <10g/dL) was 29% and hyperphosphatemia (P >5.5mg/dL), 30%. There was an increase in the frequency of use of cinacalcet and paricalcitol. The estimated overall crude annual ...

Dose-equivalency studies suggested that paricalcitol is 3–4 times less potent than calcitriol in reducing PTH in humans, 36 similar to the findings in uremic rats. Subsequently, it was suggested ...

This ‘Research Topic’ is intended to bring together experts to share their experiences in explaining the roles and regulations of vitamin D and mineral ions in various chronic human diseases. A total ...